Given that RA is a heterogeneous disease and so far the effect of denosumab in RA has been addressed only for a 12-month period, further studies are needed to investigate the inflammatory properties of RANKL in RA patients. The gene discussed is TNFSF11; the disease is rheumatoid arthritis.